These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30261781)

  • 1. Preventive effect of cyproheptadine on sleep and appetite disorders induced by methylphenidate: an exploratory randomised, double-blinded, placebo-controlled clinical trial.
    Kadkhoda Mezerji F; Moharreri F; Mohammadpour AH; Elyasi S
    Int J Psychiatry Clin Pract; 2019 Mar; 23(1):72-79. PubMed ID: 30261781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
    Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
    Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension.
    Weiss MD; Surman C; Khullar A; He E; Cataldo M; Donnelly G
    CNS Drugs; 2021 Jun; 35(6):667-679. PubMed ID: 34057707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
    Simonoff E; Taylor E; Baird G; Bernard S; Chadwick O; Liang H; Whitwell S; Riemer K; Sharma K; Sharma SP; Wood N; Kelly J; Golaszewski A; Kennedy J; Rodney L; West N; Walwyn R; Jichi F
    J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
    Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.
    Findling RL; Bukstein OG; Melmed RD; López FA; Sallee FR; Arnold LE; Pratt RD
    J Clin Psychiatry; 2008 Jan; 69(1):149-59. PubMed ID: 18312050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of methylphenidate in preschool children with ADHD.
    Wigal T; Greenhill L; Chuang S; McGOUGH J; Vitiello B; Skrobala A; Swanson J; Wigal S; Abikoff H; Kollins S; McCRACKEN J; Riddle M; Posner K; Ghuman J; Davies M; Thorp B; Stehli A
    J Am Acad Child Adolesc Psychiatry; 2006 Nov; 45(11):1294-1303. PubMed ID: 17028508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.
    Efron D; Jarman F; Barker M
    Pediatrics; 1997 Oct; 100(4):662-6. PubMed ID: 9310521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological management of treatment-induced insomnia in ADHD.
    Kratochvil CJ; Lake M; Pliszka SR; Walkup JT
    J Am Acad Child Adolesc Psychiatry; 2005 May; 44(5):499-501. PubMed ID: 15843773
    [No Abstract]   [Full Text] [Related]  

  • 12. Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial.
    Martins S; Tramontina S; Polanczyk G; Eizirik M; Swanson JM; Rohde LA
    J Child Adolesc Psychopharmacol; 2004; 14(2):195-206. PubMed ID: 15319017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
    Jain U; Hechtman L; Weiss M; Ahmed TS; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Clin Psychiatry; 2007 Feb; 68(2):268-77. PubMed ID: 17335326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADHD and insomnia.
    Cortese S; Lecendreux M; Mouren MC; Konofal E
    J Am Acad Child Adolesc Psychiatry; 2006 Apr; 45(4):384-5. PubMed ID: 16601641
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of Methylphenidate on Sleep Functioning in Children with Attention-Deficit/Hyperactivity Disorder.
    Becker SP; Froehlich TE; Epstein JN
    J Dev Behav Pediatr; 2016 Jun; 37(5):395-404. PubMed ID: 27011002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-Up.
    Weiss MD; Surman C; Khullar A; Owens J; He E; Cataldo M; Donnelly G
    J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):623-630. PubMed ID: 34714112
    [No Abstract]   [Full Text] [Related]  

  • 17. Methylphenidate dosing: twice daily versus three times daily.
    Stein MA; Blondis TA; Schnitzler ER; O'Brien T; Fishkin J; Blackwell B; Szumowski E; Roizen NJ
    Pediatrics; 1996 Oct; 98(4 Pt 1):748-56. PubMed ID: 8885956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
    Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.